Amarin Corp Plc (AMRN)

[couldbebetter]

I guess what I am trying to figure out is if AMRN were acquired by BP,
and they ran appropriate studies for new indications, lets say they were
able to achieve 5 new indications, would that add 5 years to exclusivity?
In other words how difficult would it be for a BP to continuously extent
exclusivity which would keep their revenues growing for an extended
period of time. Seems to me that any Eurocentric BP would use such
a strategy if they were confident of Vazkepa's effectiveness and utility.